Design, synthesis and biological evaluation of novel quinazoline derivatives as potential antitumor agents: molecular docking study.

Novel derivatives of quinazoline (1-27) have been synthesized and tested for their antitumor activity against three tumor cell lines among these cell lines the human breast carcinoma cell line (MCF-7) in which EGFR is highly expressed. All tested compounds showed potent and selective activity against breast cancer (MCF-7) with IC(50) range of 3.35-6.81 microg/ml. With regarding broad-spectrum activity compounds 5, 9, 15, 18 and 20 exploited potent antitumor against human liver cell line (HEPG2), human breast cell line (MCF-7) and human cervix cell line (HELA) with IC(50) range of 3.35-5.59 microg/ml. Virtual screening was carried out through docking the designed compounds into the ATP binding site of epidermal growth factor receptor (EGFR) to predict if these compounds have analogous binding mode to the EGFR inhibitors.

[1]  A. Abdel-Aziz,et al.  Synthesis and antitumor evaluation of novel diarylsulfonylurea derivatives: molecular modeling applications. , 2010, European journal of medicinal chemistry.

[2]  Sara T. A. Al-Rashood,et al.  Synthesis, dihydrofolate reductase inhibition, antitumor testing, and molecular modeling study of some new 4(3H)-quinazolinone analogs. , 2006, Bioorganic & medicinal chemistry.

[3]  H. El-kashef,et al.  Substituted quinazolines, part 3. Synthesis, in vitro antitumor activity and molecular modeling study of certain 2-thieno-4(3H)-quinazolinone analogs. , 2009, European journal of medicinal chemistry.

[4]  A. Abdel-Aziz.  Novel and versatile methodology for synthesis of cyclic imides and evaluation of their cytotoxic, DNA binding, apoptotic inducing activities and molecular modeling study. , 2007, European journal of medicinal chemistry.

[5]  M. Al-Omar,et al.  Non-classical antifolates. Part 2: synthesis, biological evaluation, and molecular modeling study of some new 2,6-substituted-quinazolin-4-ones. , 2010, Bioorganic & medicinal chemistry.

[6]  N. L. Allinger,et al.  Molecular Mechanics Calculations on Aliphatic Amines , 1985 .

[7]  K. Abouzid,et al.  Design, synthesis and in vitro antitumor activity of 4-aminoquinoline and 4-aminoquinazoline derivatives targeting EGFR tyrosine kinase. , 2008, Bioorganic & medicinal chemistry.

[8]  C. Arteaga,et al.  Tyrosine kinase inhibitors—ZD1839 (Iressa) , 2001, Current opinion in oncology.

[9]  G. Tortora,et al.  EGFR-targeting agents in oncology , 2008 .

[10]  E. Moon,et al.  Characterization of the anticancer activity of DW2282, a new anticancer agent. , 1999, Anticancer research.

[11]  Igor V Tetko,et al.  Computing chemistry on the web. , 2005, Drug discovery today.

[12]  D. Scudiero,et al.  New colorimetric cytotoxicity assay for anticancer-drug screening. , 1990, Journal of the National Cancer Institute.

[13]  T. Halgren.  Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94 , 1996, J. Comput. Chem..

[14]  D. Scudiero,et al.  Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. , 1991, Journal of the National Cancer Institute.

[15]  Miss A.O. Penney.  (b) , 1974, The New Yale Book of Quotations.

[16]  W. Bretz,et al.  Red Marine Algae Lithothamnion calcareum Supports Dental Enamel Mineralization , 2023, Marine drugs.

[17]  S. Wedge,et al.  Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. , 2002, Journal of medicinal chemistry.

[18]  I. Chung,et al.  Solid-phase combinatorial synthesis and cytotoxicity of 3-aryl-2,4-quinazolindiones. , 2002, Bioorganic & medicinal chemistry.

[19]  Qing-Shan Li,et al.  Design, synthesis and biological evaluation of chrysin long-chain derivatives as potential anticancer agents. , 2010, Bioorganic & medicinal chemistry.

[20]  Krystal J Alligood,et al.  A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib) , 2004, Cancer Research.

[21]  Suzanne F. Jones,et al.  Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  K. Gibson,et al.  Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. , 2001, Bioorganic & medicinal chemistry letters.

[23]  F. Barlesi,et al.  Gefitinib (ZD1839, Iressa®) in non‐small‐cell lung cancer: a review of clinical trials from a daily practice perspective , 2005, Fundamental & clinical pharmacology.

[24]  T. Ganesan,et al.  Tyrosine kinase inhibitors in cancer therapy. , 2004, Clinical biochemistry.

[25]  Eamonn F. Healy,et al.  Development and use of quantum mechanical molecular models. 76. AM1: a new general purpose quantum mechanical molecular model , 1985 .